Artificial Intelligence in Drug Discovery Market to Reach $8.53 Billion by 2030

Strategic Insights -

The global artificial intelligence (AI) in drug discovery market is poised for significant growth, driven by the increasing adoption of AI technologies among pharmaceutical companies. According to a report by Research and Markets, the global AI in drug discovery market was valued at $1.72 billion in 2024 and is projected to reach $8.53 billion by 2030, rising at a compound annual growth rate (CAGR) of 30.59%.

This growth is attributed to the increasing use of AI-powered technologies, including machine learning, deep learning, and natural language processing, to accelerate and optimize drug discovery processes. The integration of AI with big data and omics technologies is also driving innovation in the industry, enabling the analysis of vast and complex datasets and revolutionizing target identification, drug screening, and personalized medicine.

The report highlights the growing partnerships between pharmaceutical companies and AI-focused expertise as a significant trend in the industry. These collaborations are creating new opportunities for faster, more cost-effective, and innovative drug development. The rising costs of R&D in drug discovery are also pushing the industry to adopt innovative solutions, and AI is emerging as a powerful enabler.

The global AI in drug discovery market exhibits significant regional diversity, with North America leading the market, accounting for a global share of over 43% in 2024. The region is home to key players, innovative startups, and extensive academic and research collaborations, positioning it at the forefront of AI adoption in drug discovery.

Key Takeaways:

  • The global AI in drug discovery market was valued at $1.72 billion in 2024 and is projected to reach $8.53 billion by 2030, rising at a CAGR of 30.59%.
  • The integration of AI with big data and omics technologies is driving innovation in the industry, enabling the analysis of vast and complex datasets and revolutionizing target identification, drug screening, and personalized medicine.
  • The growing partnerships between pharmaceutical companies and AI-focused expertise are creating new opportunities for faster, more cost-effective, and innovative drug development.
  • The rising costs of R&D in drug discovery are pushing the industry to adopt innovative solutions, and AI is emerging as a powerful enabler.
  • North America leads the global AI in drug discovery market, accounting for a global share of over 43% in 2024.

Statistics:

  • The global AI in drug discovery market was valued at $1.72 billion in 2024.
  • The global AI in drug discovery market is projected to reach $8.53 billion by 2030, rising at a CAGR of 30.59%.
  • The integration of AI with big data and omics technologies is driving innovation in the industry, with the global AI in drug discovery market expected to grow at a CAGR of 35.6% from 2024 to 2030.

Sources:

  • Research and Markets, "Artificial Intelligence (AI) in Drug Discovery Market - Global Outlook & Forecast 2025-2030"
  • IBM Watson Health
  • Google DeepMind
  • NVIDIA
  • AstraZeneca
  • BenevolentAI
  • Atomwise
  • Insilico Medicine
  • Recursion Pharmaceuticals